Global Endoscopic retrograde cholangiopancreatography market - 2024-2031

Global Endoscopic retrograde cholangiopancreatography market - 2024-2031

Global Endoscopic Retrograde Cholangiopancreatography Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031

Endoscopic retrograde cholangiopancreatography is a radiologic imaging technique performed by combining both endoscopy and fluoroscopy to treat biliary disorders. This technique is majorly utilized for the diagnosis of certain disorders associated with pancreatic ductal systems.

The ERCP procedure is used to treat or diagnose issues with the pancreas or bile ducts, often causing abdominal pain and jaundice. It can open duct entry into the bowel, stretch narrow segments, remove gallstones, diagnose conditions like primary biliary cholangitis or sclerosing cholangitis, take tissue samples to diagnose tumors, and drain blocked areas. Imaging tests, such as ultrasound, CT scan, or MRI scan, are typically performed before an ERCP to diagnose the cause of symptoms.

Market Dynamics: Drivers & Restraints

The rise in the incidence of gastrointestinal and chronic biliary disorders

Gastrointestinal (GI) diseases involve different parts of the GI tract and the accessory organs of digestion like the liver, pancreas, and gallbladder. GI disorders significantly affect millions of people and are considered a major cause of global morbidity and mortality.

For instance, according to the World Gastroenterology Organisation, the prevalence of gastrointestinal disorders (GIDs) in the Philippines was found to be high, with 49% of females and 36.6% of males meeting the criteria for at least one GID. The most common disorders were functional constipation, functional dyspepsia, proctalgia fugax, functional diarrhea, and IBS.

The rates varied across countries, partly due to survey methods. Internet surveys showed more consistent patterns, with prevalence rates ranging from 33.7% in Singapore to 50% in Egypt. IBS prevalence rates were between 3 and 5%, with IBS being more common in females. Despite some exceptions, the prevalence of GIDs tended to decline with age.

High cost of ERCP devices

The high cost of ERCP devices is one of the restraining factors that hinders the market during the forecast period. For instance, the average cost of a reusable duodenoscope is $40,000. The cost of one duodenoscope reprocessing cycle with high-level disinfection in an automated endoscope reprocessor ranges from $80 to $103 per cycle.

Segment Analysis

The global endoscopic retrograde cholangiopancreatography market is segmented based on product type, application, end-user, and region.

The endotherapy devices from the product type segment accounted for approximately 39.3% of the endoscopic retrograde cholangiopancreatography market share

The endotherapy devices from the product type segment accounted for approximately 39.3%. An endoscope is a minimally invasive medical device used for observing internal organs or tissues in detail. It is used in imaging procedures and minor surgeries, such as bronchoscopes and sigmoidoscopes. Endoscopy is crucial in cancer screening, surveillance, and treatment programs. The market is expected to grow due to the increasing utility of endoscopes and technological advancements in products.

For instance, in January 2022, Cook Medical (US) launched an endoscopic clipping device, Instinct Plus, which is compatible with a duodenoscope and has applications for defect closure, anchoring procedures, and prophylactic clipping in the gastrointestinal (GI) tract.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, rise in the prevalence of pancreatic cancers, FDA approvals, high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region.

For instance, according to the American Cancer Society (ACS) 2023 report, 64,050 new pancreatic cancer cases are estimated to be diagnosed in the United States in 2023.

By Product Type
• Clinical Diagnostics
Immunochemistry
Clinical Chemistry
Cytology Testing
Genetic Testing
Others
• Pharmaceuticals
Branded/Innovator Drugs
Generics
Biosimilars
• Biologics
Blood
Vaccines
Tissue Related
• Microbiology
Sterility Testing
Endotoxin & Pyrogen Testing
Pathogen Testing
Growth Promotion Testing
Others
• Others

By Application
• Immunoassay
• Spectrometry
• Polymerase Chain Reaction
• Chromatography
• Others

By End User
• Hospitals
• Diagnostic Centers
• Pharmaceutical and Bio-application Companies
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include LGC Limited, Bio-Rad Laboratories, Merck KGaA, College of American Pathologists, Waters Corporation, FAPAS, Phenova Inc, Weqas, Advanced Analytical Solutions, LLC, Trilogy Analytical Laboratory among others.

Key Developments

 In November 2022, Shanghai Operation Robot Co, ltd announced the results of its initial clinical trial of an ERCP (Endoscopic retrograde cholangiopancreatography) robot in biliary stent placement surgery. It is the first robot-assisted human clinical trial of biliary stent placement surgery in the world.

Why Purchase the Report?
• To visualize the global endoscopic retrograde cholangiopancreatography market segmentation based on product type, application, end user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the Endoscopic Retrograde Cholangiopancreatography market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global endoscopic retrograde cholangiopancreatography market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies